Compare CHCI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCI | KROS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.9M | 206.0M |
| IPO Year | 2004 | 2020 |
| Metric | CHCI | KROS |
|---|---|---|
| Price | $16.39 | $11.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 34.9K | ★ 288.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ 0.09 | N/A |
| Revenue | $62,861,000.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $178.78 | ★ N/A |
| Revenue Growth | ★ 22.55 | N/A |
| 52 Week Low | $10.14 | $9.69 |
| 52 Week High | $19.72 | $22.55 |
| Indicator | CHCI | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 57.38 |
| Support Level | $12.94 | $10.64 |
| Resistance Level | $17.26 | $11.55 |
| Average True Range (ATR) | 0.94 | 0.50 |
| MACD | 0.18 | 0.10 |
| Stochastic Oscillator | 68.65 | 85.91 |
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.